Background/Objectives: The German IQVIA Disease Analyzer (DA) database, which contains data from more than 20 million patients in Germany, has become an important real-world data source for oncology research. This narrative review summarizes DA-based studies published between 2020 and 2025, focusing on methodological approaches, major thematic areas, and the contribution of outpatient routine data to cancer epidemiology. Methods: A structured PubMed search identified observational studies using the German DA database as the primary data source. Eligible publications examined cancer incidence, associated conditions, medication exposures, or survivorship outcomes in outpatient settings. Study designs, exposures, outcomes, and analytical strategies were synthesized qualitatively. Results: DA-based oncology studies predominantly used retrospective cohort and case–control designs. Research themes included associations between chronic inflammatory, metabolic, infectious, and cardiovascular conditions and subsequent cancer diagnoses; medication exposures and cancer incidence; and survivorship-related outcomes such as second primary cancers, fractures, and mental health disorders. Across cancer types, multimorbidity and long-term health trajectories emerged as consistent patterns. Strengths of the DA database include large unselected populations and longitudinal follow-up, while limitations relate to the absence of tumor-specific details, inpatient data, lifestyle factors, and mortality information. Conclusions: Outpatient routine data from the DA database provide valuable insights into cancer incidence, comorbidity patterns, and survivorship in real-world clinical practice. Although limited in oncological detail, DA-based studies complement registry and trial data and contribute to a broader understanding of cancer epidemiology in everyday healthcare settings.
Kostev et al. (Wed,) studied this question.